Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/9257
Title: Is bioavailability altered in generic versus brand anticonvulsants?
Authors: Jankovic, Slobodan
Ignjatović Ristić D.
Journal: Expert Opinion on Drug Metabolism and Toxicology
Issue Date: 1-Jan-2015
Abstract: © 2014 Informa UK, Ltd. Therapeutic window of anticonvulsants is not a wide one, with phenytoin being one extreme, which can be classified as a narrow therapeutic index drug, since its ratio between the least toxic and the least effective concentration is less than twofold. In order to obtain marketing authorization, a generic anticonvulsant should demonstrate relative bioequivalence with its brand-name counterpart. However, although bioequivalent, generic anticonvulsants still do not have the same bioavailability as brand-name drugs, which may lead to larger fluctuations of steady-state plasma concentrations, and sometimes to loss of seizure control if a patient is switched from brand-name to generic or from generic to generic anticonvulsant. Generic anticonvulsants are effective, safe and affordable drugs for treatment of epilepsy, and patients could be successfully treated with them from the very beginning. It is switching from brand-name to generic anticonvulsant or from one generic anticonvulsant to another that should be avoided in clinical practice, since subtle differences in bioavailability may disturb optimal degree of seizure control to which the patient was previously successfully titrated.
URI: https://scidar.kg.ac.rs/handle/123456789/9257
Type: article
DOI: 10.1517/17425255.2015.989211
ISSN: 17425255
SCOPUS: 84923025865
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)

62

Downloads(s)

4

Files in This Item:
File Description SizeFormat 
10.1517-17425255.2015.989211.pdf388.69 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons